| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology/Experimental Medicine |
From the Departments of Medicine, Pathology & Cell Biology, and Physiology & Cellular Biophysics, Columbia University, New York.
Correspondence to Ira Tabas, MD, PhD, Department of Medicine, Columbia University, 630 West 168th Street, New York, NY 10032. E-mail iat1{at}columbia.edu
Objective— Atherosclerotic plaques that are prone to disruption and acute thrombotic vascular events are characterized by large necrotic cores. Necrotic cores result from the combination of macrophage apoptosis and defective phagocytic clearance (efferocytosis) of these apoptotic cells. We previously showed that macrophages with tyrosine kinase-defective Mertk receptor (MertkKD) have a defect in phagocytic clearance of apoptotic macrophages in vitro. Herein we test the hypothesis that the MertkKD mutation would result in increased accumulation of apoptotic cells and promote necrotic core expansion in a mouse model of advanced atherosclerosis.
Methods and Results— MertkKD;Apoe–/– mice and control Apoe–/– mice were fed a Western-type diet for 10 or 16 weeks, and aortic root lesions were analyzed for apoptosis and plaque necrosis. We found that the plaques of the MertkKD;Apoe–/– mice had a significant increase in terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive apoptotic cells. Most importantly, there were more non-macrophage-associated apoptotic cells in the MertkKD lesions, consistent with defective efferocytosis. The more advanced (16-week) MertkKD;Apoe–/– plaques were more necrotic, consistent with a progression from apoptotic cell accumulation to plaque necrosis in the setting of a defective efferocytosis receptor.
Conclusion— In a mouse model of advanced atherosclerosis, mutation of the phagocytic Mertk receptor promotes the accumulation of apoptotic cells and the formation of necrotic plaques. These data are consistent with the notion that a defect in an efferocytosis receptor can accelerate the progression of atherosclerosis and suggest a novel therapeutic target to prevent advanced plaque progression and its clinical consequences.
Key Words: atherosclerosis-pathophysiology apoptosis phagocytosis animal models of human disease
Related Article:
Arterioscler. Thromb. Vasc. Biol. 2008 28: 1413-1415.
This article has been cited by other articles:
![]() |
T. Seimon and I. Tabas Mechanisms and consequences of macrophage apoptosis in atherosclerosis J. Lipid Res., April 1, 2009; 50(Supplement): S382 - S387. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C.H. Clarke and M. R. Bennett Cause or Consequence: What Does Macrophage Apoptosis Do in Atherosclerosis? Arterioscler. Thromb. Vasc. Biol., February 1, 2009; 29(2): 153 - 155. [Full Text] [PDF] |
||||
![]() |
D. Liao, X. Wang, M. Li, P. H. Lin, Q. Yao, and C. Chen Human protein S inhibits the uptake of AcLDL and expression of SR-A through Mer receptor tyrosine kinase in human macrophages Blood, January 1, 2009; 113(1): 165 - 174. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |